Background An estimated 36.7 million people live with HIV/AIDS in 2015, with more than 3 million people living with the virus in Nigeria, ranking the country among the top three most affected. Because adults are mostly affected by this epidemic, their inclusion in HIV vaccine trials is of utmost importance in obtaining an effective and acceptable vaccine. This study was thus aimed at evaluating the factors determining adults (young persons) willingness‐to‐ participate (WTP) as well as their entire knowledge and perception about HIV vaccine trials. Methods Data was obtained from 3500 young persons (18‐49 years) recruited by a multi‐stage sample technique. The cross‐sectional study was carried out using a face‐to‐face interview. An informe...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...
Background: As HIV infection continues to devastate low-income countries, efforts to search for an e...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...
This study is aimed at assessing the willingness to participate in the HIV vaccine trials and the as...
HIV/AIDS continues to destroy the lives of young people especially in low-income countries. The incl...
Background/Objective: Sub-Saharan Africa is home to two-thirds of all people living with HIV/AIDS. N...
OBJECTIVE:To evaluate initial reported willingness to participate in a hypothetical HIV vaccine clin...
Background. Nigeria, the most populous country in Africa is one of the sub- Saharan nations most aff...
Background. Nigeria, the most populous country in Africa is one of the sub- Saharan nations most aff...
OBJECTIVES: To assess willingness to participate in HIV vaccine trials and possible barriers to part...
Background: As HIV infection continues to devastate low-income countries, efforts to search for an e...
Background & Objectives: In India, phase-I human clinical trials for a preventive HIV vaccine ar...
ObjectiveTo evaluate factors associated with willingness to participate in future HIV vaccine trials...
Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in su...
Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in su...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...
Background: As HIV infection continues to devastate low-income countries, efforts to search for an e...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...
This study is aimed at assessing the willingness to participate in the HIV vaccine trials and the as...
HIV/AIDS continues to destroy the lives of young people especially in low-income countries. The incl...
Background/Objective: Sub-Saharan Africa is home to two-thirds of all people living with HIV/AIDS. N...
OBJECTIVE:To evaluate initial reported willingness to participate in a hypothetical HIV vaccine clin...
Background. Nigeria, the most populous country in Africa is one of the sub- Saharan nations most aff...
Background. Nigeria, the most populous country in Africa is one of the sub- Saharan nations most aff...
OBJECTIVES: To assess willingness to participate in HIV vaccine trials and possible barriers to part...
Background: As HIV infection continues to devastate low-income countries, efforts to search for an e...
Background & Objectives: In India, phase-I human clinical trials for a preventive HIV vaccine ar...
ObjectiveTo evaluate factors associated with willingness to participate in future HIV vaccine trials...
Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in su...
Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in su...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...
Background: As HIV infection continues to devastate low-income countries, efforts to search for an e...
ObjectivesTo assess willingness to participate (WTP) in hypothetical Phase III preventive HIV vaccin...